The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Stapled peptide sulanemadlin for AML and MDS
The stapled peptide sulanemadlin (formerly ALRN-6924) is the first known to simultaneously target two important p53 inhibitors; murine double minute-X (MDMX) and murine double minute-2 (MDM2), restoring the ability of p53 to induce cell cycle arrest and apoptosis in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Here, David Sallman, MD, of the Moffitt Cancer Center, Tampa, FL, tells us about the promising preliminary data from the Phase I/Ib dose escalation study, which evaluated this agent alone and in combination with cytarabine. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
